Cargando…
Sarcoidosis‐like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response
Neoadjuvant chemoimmunotherapy has demonstrated improved efficacy and prognosis in stage IIa–IIIb patients with non‐small cell lung cancer (NSCLC). Drug‐induced sarcoidosis‐like reaction (DISR), an autoimmune reaction, has been reported as a type of immune‐related adverse event that may mimic diseas...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671890/ https://www.ncbi.nlm.nih.gov/pubmed/34761878 http://dx.doi.org/10.1111/1759-7714.14228 |